June 24, 2019 / 8:20 PM / 22 days ago

Conatus Pharma to explore options, liver disease drug fails trial

June 24 (Reuters) - Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options.

Separately, the company said it is discontinuing the development of its liver disease drug, emricasan, after it failed to meet the main goal in a mid-stage study. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below